NIKA Pharmaceuticals, Inc. reported no revenue and continued net losses in its latest quarterly filing, reflecting its early-stage development status and heavy investment in proprietary pharmaceutical rights. The company’s business model pivots on exclusive manufacturing and distribution agreements for patented drugs like Thymus Nuclear Glycoprotein (TNG) and dietary supplements such as Carotilen and Physiolong. Strategic moves include expanding geographic reach via controlling stakes in European manufacturing facilities and joint ventures developing patented medicinal products. However, significant risks persist from low liquidity, lack of formal governance policies, and the absence of current revenue streams, constraining growth trajectories despite the structural moat from exclusive product IP and long-term partner contracts.